Home / Market Update / Gilead Sciences: We’ll Be Able to Make Enough Remdesivir in October

Gilead Sciences: We’ll Be Able to Make Enough Remdesivir in October

Biotech company Gilead Sciences said it will be able to produce enough anti-coronavirus drug Remdesivir to meet global demand in October.

In addition, Gilead said it plans to produce more than 2 million “treatment courses” for the drug by the end of the year, and expects to be able to produce “several million more” in 2021.

The company also added that it has increased the supply of the drug more than 50-fold since January.

Check Also

Canadian Dollar Gives Up Gains as Geopolitical Risks and Fed Outlook Lift US Dollar

As geopolitical uncertainty strengthens demand for the greenback, the Canadian Dollar surrendered much of its …